Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:44 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:44 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Syneos Health (SYNH) Collaborates With uMotif for New Platform
by Zacks Equity Research
Syneos Health (SYNH) partners with uMotif to deliver the patient-centric eClinical platform.
Medtronic's (MDT) MiniMed 780G System Favored by New Data
by Zacks Equity Research
Medtronic (MDT) presents the clinical and real-world data on the MiniMed 780G system at ADA Scientific Sessions in San Diego.
Lantheus Holdings (LNTH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $92.52, moving +0.81% from the previous trading session.
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Haemonetics (HAE) Gets FDA Clearance for NexSys PCS Upgrades
by Zacks Equity Research
Haemonetics (HAE) receives FDA clearance for the advancements made to the NexSys PCS plasma collection system.
CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs
by Zacks Equity Research
CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.
STERIS (STE) Buys Surgical Instrumentation Platform From BDX
by Zacks Equity Research
STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.
Lantheus Holdings (LNTH) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Lantheus Holdings (LNTH) closed at $92.20, marking a -0.72% move from the previous day.
Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches
by Zacks Equity Research
Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.
SenesTech (SNES) New Alliance to Aid Expansion in South Africa
by Zacks Equity Research
NSPCA is also working on recommending SenesTech's (SNES) ContraPest to private and state entities and to assist with regulatory issues.
Insulet (PODD) Launches the Omnipod 5 AID System in the UK
by Zacks Equity Research
Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.
Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced
by Zacks Equity Research
Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.
Bet on These 4 Top-Ranked Liquid Stocks for Robust Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Chipotle Mexican Grill (CMG), Meta Platforms (META), Lantheus Holdings (LNTH) and eGain (EGAN), which investors can add to their portfolio for solid gains.
Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes
by Zacks Equity Research
Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.
QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing
by Zacks Equity Research
The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.
Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection
by Zacks Equity Research
The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.
ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs
by Zacks Equity Research
ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.
CVS Health (CVS) Invests in Renewable Energy With New Pact
by Zacks Equity Research
CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.
Lantheus Holdings (LNTH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $86.20, moving +0.3% from the previous trading session.
Charles River's (CRL) Improved Volume Aids Amid Margin Woe
by Zacks Equity Research
Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.
Charles River (CRL) Introduces LVV Packaging Plasmids
by Zacks Equity Research
Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.
Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe
by Zacks Equity Research
Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.
Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer
by Zacks Equity Research
Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.
Here is What to Know Beyond Why Lantheus Holdings, Inc. (LNTH) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.
Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform
by Zacks Equity Research
Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.